A Phase 3 interventional study of Adalimumab 40 mg eow or ew in Crohn's Disease, sponsored by Abbott. Completed at 43 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-11.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 18th largest by enrollment, is one of 3 that started in 2002, is one of 22 in phase 3, and was the 16th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
17 studies in Crohn Disease by Abbott: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 17 studies in Crohn Disease by Abbott, this one is the 11th largest by enrollment, is one of 4 that started in 2002, is one of 10 in phase 3, and was the 17th registered.
Abbott’s Crohn Disease studies by the year they started, since 2002.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 17 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.
Study M02-433 was designed to evaluate the efficacy and safety of adalimumab in the maintenance of clinical remission in patients with Crohn's disease (CD). The study consisted of 2 phases: 1. a 1-year phase (Week 0 to Week 56) (NCT00055497) that consisted of a randomized, double-blind, placebo-controlled portion with a concomitant open label (OL) portion, and 2. a long-term open-label extension (OLE) phase (NCT01070303) that lasted 264 additional weeks (Week 56 to Week 320).
Participants who completed the lead-in study NCT00055523, were eligible to participate in the rollover study, NCT00055497. 176 participants were documented as having completed Year 1 (NCT00055497); however, 177 participants were still receiving study drug and were evaluated at Week 56 of NCT00055497; these participants are included in the OLE data (NCT01070303).
At Week 4 of NCT00055497, participants who demonstrated clinical remission (defined as a Crohn's Disease Activity Index [CDAI] score \<150 points) at Baseline of NCT00055497 and who remained in clinical remission at Week 4 ("Remitters") were randomized to receive 1 of 3 blinded treatments: placebo, adalimumab 40 mg every other week (eow), or adalimumab 40 mg every week (ew). Participants who did not demonstrate clinical remission at Baseline of NCT00055497 or who were no longer in clinical remission at Week 4 of NCT00055497 ("Non-remitters") were assigned to receive OL adalimumab 40 mg eow. All study drug (placebo and active) was administered by subcutaneous (SC) injection.
At any time during Study NCT00055497, a participant receiving blinded study drug who developed a disease flare could be switched to OL adalimumab 40 mg eow. A participant receiving OL adalimumab 40 mg SC eow who developed a flare or was a non-responders could have had his/her dose increased to 40 mg SC ew.
After 1 year (Week 56 of NCT00055497), patients who were still participating could continue in the OLE phase (NCT01070303). Participants who were receiving blinded study drug were switched to OL adalimumab 40 mg SC eow, and participants who were receiving OL study drug continued on their previous OL adalimumab dose (adalimumab 40 mg SC eow or ew).
Data are summarized for Remitters and Non-remitters, with the exception of data for primary reason for noncompletion. Summaries of primary reason for noncompletion were available only for all participants, not for Remitters and Non-remitters. Data are reported for Weeks 104, 152, 212, and 260 of Study M02-433, starting from Week 0 of NCT00055497; these weeks correspond to 1, 2, 3, and 4 years of participation in NCT01070303. Change from Baseline results (clinical response 70, clinical response 100, Inflammatory Bowel Disease Questionnaire, and fistula remission) are calculated from Baseline of the lead-in study (NCT00055523). Results on each assessment at each measurement time point are presented as individual outcome measures because different numbers of participants were evaluated at each time point (as observed analysis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Adalimumab 40 mg eow or ew
Adalimumab 40 mg by subcutaneous injection every other week or every week
Also known as: Adalimumab, Humira
Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
Time frame: Week 104
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
Time frame: Week 152
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
Time frame: Week 212
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303).
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
Time frame: Week 260
Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in study to Week 104
Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in study to Week 152
Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in study to Week 212
Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in study to Week 260
Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)
A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: Week 104
Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)
A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in Study to Week 152
Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)
CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in study to Week 212
Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)
A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
Time frame: From Baseline of lead-in study to Week 260
Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
Time frame: From Baseline of lead-in study to Week 104
Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
Time frame: From Baseline of lead-in study to Week 152
Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
Time frame: From Baseline of lead-in study to Week 212
Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
Time frame: From Baseline of lead-in study to Week 260
Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
Time frame: From Baseline of lead-in study to Week 104
Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
Time frame: From Baseline of lead-in study to Week 152
Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
Time frame: From Baseline of lead-in study to Week 212
Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
Time frame: From Baseline of lead-in study to Week 260
Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores
IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each question, participants selected 1 of 7 responses, where 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality on the item (e.g., feeling of fatigue "none of the time"). IBDQ scores range from 32 to 224. Higher scores indicate better quality of life, and increases in IBDQ indicate improved overall quality of life.
Time frame: Change from Baseline of lead-in study at Weeks 104, 152, 200, and 248
Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
Time frame: From Baseline of lead-in study to Week 104
Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
Time frame: From Baseline of lead-in study to Week 152
Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
Time frame: From Baseline of lead-in study to Week 212
Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
Time frame: From Baseline of lead-in study to Week 260
Participants who were still receiving study drug and were evaluated at Week 56 of Study M02-433 (NCT00055497) are included in the open-label extension (OLE) (NCT01070303). Participants entered NCT00055497 from a lead-in adalimumab induction therapy study (NCT00055523).
| Milestone | All Participants in Open-Label Extension of Study M02-433 |
|---|---|
| Started | 177 |
| Completed | 88 |
| Not completed | 89 |
| Withdrew: Adverse event | 39 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Protocol violation | 0 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Administrative reason | 1 |
| Withdrew: Other | 18 |
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303). | 29 | 71 |
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303). | 26 | 62 |
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303). | 21 | 45 |
Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303). | 8 | 21 |
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303) | 28 | 87 |
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303) | 28 | 74 |
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303) | 23 | 58 |
A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303) | 8 | 27 |
A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303) | 31 | 92 |
A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303) | 30 | 77 |
CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303) | 24 | 63 |
A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303) | 10 | 27 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303) | 8 | 12 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303) | 8 | 14 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303) | 5 | 10 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303) | 2 | 4 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303) | 9 | 15 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303) | 9 | 15 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303) | 6 | 12 |
Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303) | 2 | 5 |
IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each question, participants selected 1 of 7 responses, where 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality on the item (e.g., feeling of fatigue "none of the time"). IBDQ scores range from 32 to 224. Higher scores indicate better quality of life, and increases in IBDQ indicate improved overall quality of life.
| Scores on a scale | Change From Baseline-Week 104 | Change From Baseline-Week 152 | Change From Baseline-Week 200 | Change From Baseline-Week 248 |
|---|---|---|---|---|
| Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores | 42.4 ± 36.27 | 47.9 ± 33.70 | 51.0 ± 32.77 | 51.7 ± 32.67 |
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303) | 1 | 11 |
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303) | 2 | 11 |
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303) | 1 | 10 |
A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.
| Participants | Remitters | Non-Remitters |
|---|---|---|
| Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303) | 2 | 6 |
Collected over Treatment-emergent adverse events (AEs), defined as AEs beginning on or after first dose of adalimumab (in NCT00055523, NCT00055497, or NCT01070303) are reported. Treatment-emergent AEs were recorded up to 70 days after last dose of adalimumab.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Remitters | — | 6/55 (10.9%) | 50/55 (90.9%) |
| Non-Remitters | — | 69/221 (31.2%) | 207/221 (93.7%) |
| Event | Remitters | Non-Remitters |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/55 | 17/221 |
| Small intestinal obstructionGastrointestinal disorders | 0/55 | 8/221 |
| Coronary artery diseaseCardiac disorders | 1/55 | 1/221 |
| Colonic stenosisGastrointestinal disorders | 1/55 | 1/221 |
| ConstipationGastrointestinal disorders | 1/55 | 0/221 |
| Ileal stenosisGastrointestinal disorders | 1/55 | 3/221 |
| Intestinal obstructionGastrointestinal disorders | 1/55 | 1/221 |
| Small intestinal stenosisGastrointestinal disorders | 1/55 | 3/221 |
| PneumoniaInfections and infestations | 1/55 | 0/221 |
| Back painMusculoskeletal and connective tissue disorders | 1/55 | 0/221 |
| Event | Remitters | Non-Remitters |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 23/55 | 70/221 |
| NasopharyngitisInfections and infestations | 15/55 | 50/221 |
| NauseaGastrointestinal disorders | 8/55 | 51/221 |
| Abdominal painGastrointestinal disorders | 12/55 | 42/221 |
| HeadacheNervous system disorders | 8/55 | 47/221 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/55 | 43/221 |
| Injection site irritationGeneral disorders | 9/55 | 21/221 |
| DiarrhoeaGastrointestinal disorders | 8/55 | 36/221 |
| SinusitisInfections and infestations | 6/55 | 34/221 |
| PyrexiaGeneral disorders | 5/55 | 33/221 |
| Age Continuous(years) | Remitters | Non-Remitters | Total |
|---|---|---|---|
| Mean | 35.5 ± 10.88 | 38.9 ± 12.53 | 38.1 ± 12.19 |
| Sex: Female, Male(Participants) | Remitters | Non-Remitters | Total |
|---|---|---|---|
| Female | 26 | 60 | 86 |
| Male | 19 | 72 | 91 |
| Region of Enrollment(participants) | Remitters | Non-Remitters | Total |
|---|---|---|---|
| United States | 45 | 132 | 177 |
The record gives a start of Aug 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab